Cancer immumotherapy: Avoiding the road to perdition

Maurizio Chiriva-Internati, Fabio Grizzi, Robert K. Bright, W. Martin Kast

Research output: Contribution to journalArticlepeer-review

Abstract

The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.

Original languageEnglish
Article number26
JournalJournal of Translational Medicine
Volume2
DOIs
Publication statusPublished - Jul 29 2004

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Cancer immumotherapy: Avoiding the road to perdition'. Together they form a unique fingerprint.

Cite this